1 / 42

Bullous Pemphigoid: Is prednisone the only option?

Bullous Pemphigoid: Is prednisone the only option?. Wynnie Lau Pharmacy Resident 2010-2011 Medicine Rotation 8 September 2010. Outline. Case Background Clinical Question Discussion of evidence Case conclusion/recommendations. Case of MK. Case of MK. Case of MK. Diagnosis.

magar
Download Presentation

Bullous Pemphigoid: Is prednisone the only option?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Bullous Pemphigoid: Is prednisone the only option? Wynnie LauPharmacy Resident 2010-2011Medicine Rotation 8 September 2010

  2. Outline • Case • Background • Clinical Question • Discussion of evidence • Case conclusion/recommendations

  3. Case of MK

  4. Case of MK

  5. Case of MK

  6. Diagnosis • 17 Aug @ VGH dx Bullous Pemphigoid • Started clobetasol 0.05% ung applied BID to AA and Prednisone 90mg (1mg/kg) • 23 August pathology confirmed dx with linear IgG + C3 deposit along basement membrane zone from L upper thigh

  7. Bullous Pemphigoid Ref 1-2

  8. Bullous Pemphigoid Ref 1

  9. Bullous Pemphigoid Ref 3-5

  10. Bullous Pemphigoid Drug induced BP • Approximately 30 medications suspected in past • Frequently involve diuretics and neuroleptic drugs • Among the list include ACE inhibitors especially captopril, enalapril • Hypothesized that drugs may change antigenicity to induce synthesis of antibodies against basal membrane zone Ref 5-6

  11. Bullous Pemphigoid Ref 3

  12. MK’s DRPs • MK is at risk of death secondary to long term use of systemic corticosteroids and would benefit from a reassessment of his bullous pemphigoid treatment • MK is at risk for infections secondary to open blisters as a result of his bullous pemphigoid and would benefit from a reassessment of his bullous pemphigoid treatment • MK is experiencing continued pruritus secondary to his bullous pemphigoid and would benefit from a reassessment of his bullous pemphigoid treatment • MK is experiencing a 14 day history of worsening rash and blisters secondary to his bullous pemphigoid and would benefit from a reassessment of his bullous pemphigoid treatment • MK is experiencing continued erythema, blisters and pruritus secondary to improper treatment with cephalexin for his bullous pemphigoid, an autoimmune disorder and would benefit from a reassessment of his bullous pemphigoid treatment • MK is experiencing continued erythema, blisters and pruritus secondary to improper treatment with fusidan cream for his bullous pemphigoid, an autoimmune disorder and would benefit from a reassessment of his bullous pemphigoid treatment • MK is experiencing continued erythema, blisters and pruritus secondary to improper treatment with acyclovir for his bullous pemphigoid, an autoimmune disorder and would benefit from a reassessment of his bullous pemphigoid treatment • MK is at risk of mortality secondary to increased blood pressures due to his held ramipril and requires close monitoring of his blood pressure treatment • MK is at risk for deep vein thrombosis clot secondary to being bed bound and immobile and would benefit from a reassessment of his DVT prophylaxis • MK is at risk for a cardiovascular event currently taking a statin and would benefit from an assessment of his lipid levels

  13. Clinical Question

  14. Search strategy • Terms: Bullous Pemphigoid, Pemphigoid, Prednisone, methotrexate, azathioprine, cyclophosphamide, cyclosporine • Limits: Humans • Databases searched: PubMED, Medline, EMBASE • 1 Systematic Review • RCTs – 7 (5 French) • Open label prospective – 5 (1 German) • Retrospective analysis – 4 • Case report – 2

  15. Summary

  16. Review of Evidence

  17. A retrospective analysis of patients with bullous pemphigoid treated with methotrexate Petra Kjellman, Hanna Eriksson, Peter Berg Arch Dermatol 2008; 144(5):612-616 Ref 8

  18. Kjellman et al

  19. Kjellman et al • 145 pt dx – 7 lost to follow up and excluded • 138 pt incl – 98 began MTX w median 5mg/wk dose • 61 continued with MTX mono-therapy • Weekly median 5mg (2.5-17.5mg) • Median cumulative dose 280mg (15-3280mg) • 37 given MTX + prednisone • Median weekly 6mg (2.5-15mg) • Median cumulative dose 440mg (30-2250mg)

  20. Kjellman et al • 40 pt did not receive MTX • 15 – treated with HD prednisone alone • 4 patients had anemia/renal insufficiency • 1 already taking cytotoxic drugs • 5 due to MD preference • 5 d/c MTX due to AE (2GIT, 1 anemia in 3 weeks, 1 ↑ liver enzymes, 1 alveolitis) • 25 used betamethasone gel only due to mild disease

  21. Kjellman et al

  22. Kjellman et al

  23. Kjellman et al - Results

  24. Kjellman et al conclusions • Low dose MTX + topical betamethasone safe and effective (maximum, MTX 12.5mg/wk) • Topical tx alone sufficient for mild • MTX did not reduce expected life span • AE includes • 2 GIT irritation – after first dose • 1 Transient alveolitis – after 3 wks • 1 anemia • 1 increased liver enzyme levels

  25. Kjellman et al • Limitations • Retrospective study • Relation between severity of disease and time to remission could not be proved significant due to low #s • Higher hospital admission days in MTX+Pred reflects low # of pt with mild disease in group • Unable to identiy spectrum of responders, partial responders and nonresponders or duration of therapy in each of groups nor % distribution

  26. Treatment of Bullous Pemphigoid by Low-Dose Methotrexate Associated with short term potent topical steroids: an open prospective study of 18 cases Dereure, O; Bessis D; Guillot B; Guilhous J-J Arch Dermatol 2002; 138 Ref 9

  27. Dereure et al

  28. Dereure et al - Results

  29. Dereure et al conclusions • 17 pt – maintained on MTX monotherapy for 8months and 13 able to stop after • Adverse events • 5 patients weary after 3 months w/o significant liver test disruptions • Asymptomatic HgB decrease in 6pts • 10/16 showed disappearance of immune deposits done 2 mo after remission

  30. Dereure et al- conclusions • Clobetasol topical + MTX with MTX continued • Good tolerance overall at 8 months with asymptomatic HgB decrease observed in 6/18 • 8-10mo MTX to obtain persistent remission

  31. Dereure et al • Limitations • Small study • Unknown degree of disease severity • Non-comparative • Unknown disease severity of patients involved • Total duration needed to achieve long last response unknown

  32. Summary

  33. Back to MK…

  34. Monitoring Plan

  35. Monitoring Plan

  36. References • Goldstein, BG and Goldstein A. Bullous Pemphigoid and other pemphigoid disorders. UptoDate. Last lit review May2010. • Lipsker Dan and Borradori Luca. Bullous Pemphigoid: what are you? Urgent need of definitions and diagnostic criteria. Dermatology. 2010. • Mutasim, DF. Autoimmune Bullous Dermatoses in the elderly: an update on pathophysiology, diagnosis and management. Drugs Aging. 2010:27(1):1-19. • Zhu Yi, Fitzpatrick JE< Kornfeld BW. Lichen planus pemphigoides associated with ramipril. Int J Dermatol. 2006 Dec; 45(12):1453-5. • Lee JJ, Downham TF 2nd. Furosemide-induced bullous pemphigoid: case report and review of literature. J Drugs Dermatol. 2006 June; 5(6):562-4. • Walsh SR, Hogg D, mydlarski PR. Bullous pemphigoid: from bench to bedside. Drugs. 2005; 65(7):905-26. • Rzany Berthold et al. Risk factors for lethal outcome in patients with bullous pemphigoid. Arch Dermatol. 2002; 138: 903-908. • Kjellman P, Eriksson H, Berg P. A retrospective analysis of patients with bullous pemphigoid treated with methotrexate. Arch Dermatol 2008; 144(5):612-616 • Dereure O et al. Treatment of Bullous Pemphigoid by Low-Dose Methotrexate Associated with short term potent topical steroids: an open prospective study of 18 cases. Arch Dermatol 2002; 138

  37. Low dose oral pulse methotrexate as monotherapy in elderly patients with bullous pemphigoid Johan Heilborn, Mona Stahle – Backdahl, Freidun Albertioni, Ismini Vassilaki, Curt Peterson, Eija Stephansson J am acad Dermatol 1999; 40:741-9

  38. Heilborn et al

  39. Heilborn et al

  40. Heilborn et al

  41. Heilborn et al - results

  42. Heilborn et al • Side effects • 2 pt died w/o indication MTX was cause • Decrease HgB 20-35% in 5 patients obs in 1st wk which normalized over time w/o change in MTX • 1 nausea & lack of appetite given folic acid 6d/wk • 1 given abx because of erysipelas during beginning of mtx w/o drop in WBC to suggest MTX cause

More Related